Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Celgene Expands In Epigenetics
by Lisa M. Jarvis
August 5, 2013
| A version of this story appeared in
Volume 91, Issue 31
Celgene will pay Acetylon Pharmaceuticals $100 million up front to develop three drug candidates that block histone deacetylases, enzymes that remove an amino group from histone, thereby regulating DNA expression. The deal includes an option for Celgene to acquire the Boston-based epigenetics firm for up to $1.1 billion. The pact is Celgene’s second in epigenetics. Last year, the firm paid Epizyme $90 million to develop drugs that inhibit a class of epigenetic enzymes called histone methyltransferases.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter